07.18.23 -- Key Considerations For Developing Next-Generation Antibody-Drug Conjugates

To meet ambitious orphan drug development timelines, CDMOs must be able to scale quickly to progress from early clinical development to validation and commercial launch.

As the field of biologics increases its focus on identifying new diseases to target and novel constructs to treat them, innovative administration devices are once again in the spotlight.

An immediate need for lower-dose capsules in the clinic posed several challenges in blend formulation with very tight timelines for delivery.

Learn more about the production benefits imposed using MDCK cells that have the potential to significantly reduce lead times for vaccine production and alleviate constraints on raw material supply.

Critical quality attributes are fundamental to regulatory compliance. Discover how different analytical technologies have been used to evaluate the efficacy, stability, and safety of therapeutic candidates.

Learn the pros and cons of soluble and insoluble processes: isolating, solubilizing, and properly refolding, and strategies to improve the performance of IB processes.